
Northwestern Medicine scientists have discovered how disruptions in circadian rhythm impair metabolic function in fat cells, providing new insights into the molecular mechanisms that cause obesity and metabolic disease, according to a recent study published in Nature Metabolism.

Feinberg’s chapter of the Alpha Omega Alpha (AOA) medical honor society welcomed 41 new members during a ceremony on March 3, recognizing outstanding educational achievements and contributions to medicine.

CAR T-cell immunotherapy improved progression-free and overall survival in patients with relapsed or refractory marginal zone lymphoma, according to a recent clinical trial published in The Lancet.

An advanced machine learning model predicted spoken language outcomes in children who received cochlear implants more accurately than traditional machine learning approaches, according to a recent Northwestern Medicine-led international multi-center study.

Robert J. Lefkowitz, MD, the Chancellor’s Distinguished Professor of Medicine and professor of Biochemistry and Chemistry at Duke University School of Medicine, will address graduates and their guests as the commencement speaker at Feinberg’s 2026 commencement.

A new study has shed light on why patients with certain rare immune disorders develop severe, food‑triggered allergic reactions while others with similar diagnoses do not.

Northwestern Medicine scientists have discovered a potent immunotherapy approach for treating meningiomas, the most common type of primary brain tumor, according to a recent study published in Nature Communications.

Northwestern Medicine scientists have identified cellular mechanisms that cause immune cells to differentiate and ultimately lose function during viral infection, findings that could improve therapeutic strategies for controlling chronic infection, according to a recent study.

Amy S. Paller, MD, the chair and Walter J. Hamlin Professor of Dermatology, will be stepping down as chair after more than two decades of transformative and visionary leadership.

Northwestern University scientists have pinpointed when and where toxic proteins accumulate within the brains of Alzheimer’s patients — and discovered a decades-old Food and Drug Administration (FDA)-approved drug that can stop the accumulation process before it even begins, according to a recent study published in Science Translational Medicine.